Section Review: Biologicals & Immunologicals: Applications of antisense technology to both basic and clinical research

References

• WEINTRAUB HM: Antisense RNA and DNA. Sci. Am. (1990) 262:40–46.
   Google Scholar
• HELENE C, TOULME J: Specific regulation of gene expres-sion by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta (1990) 1049:99–125.
   PubMed Web of Science ®Google Scholar
• PATEFtSON BM, ROBERT BE, ICUFF EL: Structural gene Identification and mapping by DNA-mRNA hybrid-ar-rested cell-free translation. Proc. NatL Acad. Sci. USA (1977) 74:4370–4374.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK PC, STEPHENSON ML: Inhibition of bussarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280–284.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Progress toward oligonucleotkle therapeu-tics: pharroacodynamicproperties. FASEBI (1993) 7:533–539.
   PubMed Web of Science ®Google Scholar
• BAERTSCHI AJ: Antisense oligonucleotide strategies in physiology. Mol. Cell. Endocrin. (1994) 101:R15–R24.
   PubMed Web of Science ®Google Scholar
• HELENE C: The anti-gene strategy control of gene ex-pression by triplex-forming-oligonucleotides. Anti-Cancer Drug Design (1991) 6:569–584.
   PubMedGoogle Scholar
• NIELSEN PE, EGHOLM M, BERG RH, BUCHARDT 0: Science(1991) 254:1497–1500.
   Google Scholar
• GILES RV, TIDD DM: Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides. Anti-Cancer Drug De-sign (1992) 7:37–48.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C: Antisense ofigonucleotkle strategies in neuropharinacology. Trends Pharmacol. Sci. (1994) 15:42–46.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R: Inhibition of protein kinase C-al-pha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA (1994) 91:11762–11766.
   PubMed Web of Science ®Google Scholar
• WAGNER RW: Gene inhibition using antisense oligode-oxynucleotides. Nature (1994) 372:333–335.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S: Antisense oligonucleotides as antiviral agents. Trends Biotech. (1992) 10:152–158.
   PubMed Web of Science ®Google Scholar
• NIELSEN PE, EGHOLM M, BERG RH, BUCHARDT 0: Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anti-cancer Drug Design (1993) 8:53–63.
   PubMedGoogle Scholar
• JOHANSSON HE, BELSHAM GJ, SPROAT BS, HENTZE MW: Target-specific arrest of mRNA translation by antisense 2'-0-alkylollgoribonucleotides. Nucleic Acids Res. (1994) 22:4591–4598.
   PubMed Web of Science ®Google Scholar
• BONHAM MA, BROWN S, BOYD AL, BROWN PH, BRUCK-ENSTEIN DA, HANVEY JC, THOMSON SA, PIPE A, HASS-MAN F, BISI JE, FROEHLER BC, MAITEUCCI MD, WAGNER RW, NOBLE SA, BABISS LE: An assessment of the antis-ense properties of RNase H-competent and steric-block-ing oligomers. Nucleic Acids Res. (1995) 23:1197–1203.
   PubMed Web of Science ®Google Scholar
• HERSCHLAG D: Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proc. NatL Acad. Sci. USA (1991) 88:6921–6925.
   PubMed Web of Science ®Google Scholar
• CAZENAVE C, LOREAU N, THUONG NT, TOULME JJ, HELENE C: Enzymatic amplification of translation inhi-bition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents. Nucleic Acids Res. (1987) 15:4717–4736.
   PubMed Web of Science ®Google Scholar
• BOIZIAU C, THUONG NT, TOLTLME JJ: Mechanisms of the Inhibition of reverse transcription by antisense oli-gonucleotides. Proc. Natl. Acad. Sci. USA (1992) 89:768–772.
   PubMed Web of Science ®Google Scholar
• WOOLF TM, MELTON DA, JENNINGS CGB: Specificity of antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA (1992) 89:7305–7309.
   PubMed Web of Science ®Google Scholar
• ICLEUSS C, SCHULTZ G, WITTIG B: Microinjection of antisense oligonucleotides to assess G-protein subunit function. Methods Enzymol. (1994) 237:345–355.
   PubMed Web of Science ®Google Scholar
• GILES RV, ULM) DM: Increased specificity for antisenseoligodeoxynucleotide targeting of RNA cleavage by RNase II using chimeric methylphosphonodi-ester/phosphodiester structures. Nucleic Acids Res. (1992) 20:763–770.
   PubMed Web of Science ®Google Scholar
• WEIDNER DA, BUSCH H: Antisense phosphorothioate oligonucleotides direct both site-specific and nonspe-cific RNase H cleavage of in afro synthesized p120 mRNA. Oncology Res. (1994) 6:237–242.
   PubMed Web of Science ®Google Scholar
• GAO W-Y, HAN F-S, STORM C, EGAN W, CHENG Y-C: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase lb Implications for antisense technology. Molec. Pharmacol (1992) 41:223–229.
   PubMed Web of Science ®Google Scholar
• BROWN DA, KANG S-H, GRYAZNOV SM, DEDIONISIO L,HEIDENREICH 0, SULLIVAN S, XU X, NERENBERG MI: Effect of phosphorothioate modification of oligode-oxynucleotides on specific protein binding. J. Biol. Chem. (1994) 269:26801–26805.
   PubMedGoogle Scholar
• STEIN CA, KRIEG AM: Problems in interpretation of dataderived from in vitro and in vivo use of antisense oligodeoxynucleotides [editorial]. Antisense Res. Dev. (1994) 4:67–69.
   PubMedGoogle Scholar
• PEREZ JR, LI Y, STEIN CA, MAJUMDER S, VAN OORSCHOTA, NARAYANAN R: Sequence-independent induction of Spl transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA (1994) 91:5957–5961.
   PubMed Web of Science ®Google Scholar
• COHEN JS: Antisense oligodeoxynucleotides as antiviral agents. Antivir. Res. (1991) 16:121–133.
   PubMed Web of Science ®Google Scholar
• BISCHOFBERGER N, WAGNER RW: Antisense approaches to antiviral agents. Semin. Virol. (1992) 3:57–66.
   Google Scholar
• RATHBONE MP, MIDDLEMISS PJ, GYSBERS JW, DEFORGE S, COSTELLO P, MAESTRO RFD: Purine nucleosides and nucleotides stimulate proliferation of a wide range of cell types. In vitro Cell Dev. Biol. (1992) 28A:529–536.
   PubMed Web of Science ®Google Scholar
• ICAMANO H, TANAICA T, YAMAJI Y, IKEDA K, HATA Y, SHIOTANI T, ISHIDA T, TAKAHARA J, IRINA S: L colt gist gene expression effects on K562 human leukemia cell proliferation and erythroid differentiation altered by mycophenolic acid. Biochem. Int. (1992) 26.
   Google Scholar
• KLEUSS C, SCHERUBL H, HESCHELER J, SCHULTZ G, WiT-TIG B: Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science (1993) 259:832–834.
   PubMed Web of Science ®Google Scholar
• ALBERT PR, MORRIS SJ: Antisense knockouts: molecular scalpels for the dissection of signal transduction. Trends PharmacoL Sci. (1994) 15:250–254.
   PubMed Web of Science ®Google Scholar
• SIMONS M, EDELMAN ER, DEKEYSER J-L, LANGER R, ROSENBERG RD: Antisense c-myb oligonucleotides in-hibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 359:67–70.
   PubMed Web of Science ®Google Scholar
• ERLINGE D, EDVINSSON L, BRUNKWALL J, YEE F, WA- HLESTEDT C: Human neuropeptide Y Y1 receptor antis-ease oligodeoxynucleotide specifically inhibits neuropeptide Y-evoked vasoconstriction. Eur. j Phar-macol. (1993) 240:77–80.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, PICH EM, KOOB GF, YEE F, HEIUG M: Modulation of anxiety and neuropeptide Y-Y1 recep-tors by antisense oligodeoxynucleotides. Science (1993) 259:528–531.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, GOLANOV E, YAMAMOTO S, YEE F, ERICSON H, YO0 H, INTURRISI CE, REIS DJ: Antisense oligodeoxynucleotides to NMDA-Rl receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature (1993) 363:260–263.
   PubMed Web of Science ®Google Scholar
• STANDIFER KM, CHIEN CC, WAHLESTEDT C, BROWN GP, PASTERNAK GW: Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron (1994) 12:805–810.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB H: The myoD family and myogenesis: re-dundancy, networks, and thresholds. Cell (1993) 75:1241–1244.
   PubMed Web of Science ®Google Scholar
• ROUTTENBERG A: Knockout mouse fault lines. Nature(1995) 374.
   Google Scholar
• WAGNER RW, MATTEUCCI MD, LEWIS JG, GUIIERREZ AJ,MOULDS C, FROEHLER B C: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (1993) 260:1510–1513.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, CONDON TP, BENNETT CF: Inhibi-tion of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induc-tion of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. (1994) 269:16416–16424.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, CONDON TP, GRIMM S. CHAN H, CHIANGMY: Inhibition of endothelial cell adhesion molecule expression with antisense oligonuckotides. j ImmunoL (1994) 152:3530–3540.
   Google Scholar
• STULL RA, TAYLOR LA, SZOKA FC: Predicting antisenseoligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indi-ces. Nucleic Acids Res. (1992) 20:3501–3508.
   PubMed Web of Science ®Google Scholar
• WATKINS DC, JOHNSON GL, MALBON CC: Regulation ofthe differentiation of teratocarcinoma cells into primi-tive endoderm by Gam Science (1992) 258:1373–1375. 38.
   Google Scholar
• KLEUSS C, HESCHELER J, EWEL C, ROSENTHAL W, SCHLTLTZ G, WITTIG B: Assignment of G-protein sub-types to specific receptors inducing inhibition of cal-cium currents. Nature (1991) 353:43–48.
   PubMed Web of Science ®Google Scholar
• BENNETT EM, GABOR GT, MERRITT MM: DNA binding to human leukocytes. I din. Invest. (1985) 12:2182–2190.
   Google Scholar
• BENNETT EM, HEFENEIDER SH, BAKKE A, MERRITT M, SMITH CA, MOURICH D, HEINRICH MC: The production and characterization of marine monoclonal antibodies to a DNA receptor on human leukocytes. J. Immunol. (1988) 140:2937–2942.
   PubMed Web of Science ®Google Scholar
• LOKE SL, STEIN CA, ZHANG XH, MORI K, NAKANISHI M,SUBASINGHE C, COHEN JS, NECKERS LM: Charac-terization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA (1989) 86:3474–3478.
   PubMed Web of Science ®Google Scholar
• BROWN ICE, KINDY MS, SONENSHEIN GE: Expression ofthe c-myb proto-oncogene in bovine vascular smooth muscle cells. J. Biol. Chem. (1992) 267:4625–4630.
   PubMed Web of Science ®Google Scholar
• STEIN CA, TONKINSON JL, ZHANG LM, YAICUBOV L, GERVASONI J, TAUB R, ROTENBERG SA: Dynamics of the internnii7ation of phosphorothioate oligodeoxynu-cleoticies in HL60 cells. Biochemistry (1993) 32:4855–4861.
   PubMed Web of Science ®Google Scholar
• TEMSAMANI J, KUBERT M, TANG J, PADMAPRIYA A, AGRAWAL S: Cellular uptake of oligodeoxynucelotide phosphorothioates and their analogs. Antinsense Res. Dev. (1994) 4:35–42.
   PubMedGoogle Scholar
• MILLIGAN JF, MATTEUCCI MD, MARTIN JC: Current con-cepts In antisense drug design. J. Med. Chem. (1993) 36:1923–1937.
   PubMed Web of Science ®Google Scholar
• CERUZZI M, DRAPER K, SCHWARTZ J: Natural and phos-phorothioate modified oligodeoxyribonucleoticles ex-hibit a non-random cellular distribution. Nucleosides Nucleotides (1990) 9:679–695.
   Web of Science ®Google Scholar
• BENNETT FC, CHIANG MY, CHAN HC, SHOEMAKER JEE, MIRABELLI CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonu-cleotkles. Mot Pharmacol. (1992) 41:1023–1033.
   PubMed Web of Science ®Google Scholar
• ZHAO Q, MATSON S, HERRERA CJ, FISHER E, YU H, KRIEG AM: Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and tnethylphosphonate oil-gonucleotides. Antisense Res. Dev. (1993) 3:53–66.
   PubMedGoogle Scholar
• FISHER TL, TERHORST T, GAO X, WAGNER RW: Intracel-lular disposition and metabolism of unmodified and modified oligonucleotides mieroinjected into mammal-ian cells. Nucleic Acids Res. (1993) 21:3857–3865.
   PubMed Web of Science ®Google Scholar
• LEONETTI JP, MECHTI N, DEGOLS G, GAGNOR G, LEBLEUB: Intracelluar distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA (1991) 88:2702–2706.
   PubMed Web of Science ®Google Scholar
• AKABAYASHI A, WAHLESTFDT C, ALEXANDER yr, LEI-BOWITZ SF: Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antis-ease oligonucleotides suppresses feeding behavior and Insulin secretion. Brain Res. Mol. Brain Res. (1994) 21:55–61.
   PubMedGoogle Scholar
• BILSKY EJ, BERNSTEIN RN, PASTERNAK GW, HRUBY VJ,PATEL D, PORRECA F, LAI J: Selective inhibition of [D-Ala2, Ght4]deltorphin antinociception by supraspi-nal, but not spinal, administration of an antisense oligodeox-ynucleotide to an opioid delta receptor. Life Sci. (1994) 55:L37–43.
   Google Scholar
• YEE F, ERICSON H, REIS DJ, WAHLESTEDT C: Cellular uptake of intracerebroventricularly administered bio-tin- or digoxigenin-labeled antisense oligodeoxynu-cleotides in the rat. Cell Mot Neurobiol. (1994) 14:475–486.
   Web of Science ®Google Scholar
• STEIN CA, TONKINSON JL, YAKUBOV L: Phos-phorothioate oligodeoxynucleotides - anti-sense in-hibitors of gene expression? Pharmacol. 7ber. (1991) 52:365–384.
   Google Scholar
• CHIASSON BJ, HOOPER ML, MURPHY PR, ROBERTSON HA:Antisense oligonucleotide eliminates in vivo expres-sion of c-fos in mammalian brain. Ear. J. Pharmacol. (1992) 227:451–453.
   PubMed Web of Science ®Google Scholar
• HEILIG M, ENGEL JA, SODERPALM B: C-fos antisense inthe nucleus accurabens blocks the locomotor stimulant action of cocaine. Earl Pharmacol. (1993) 236:339–340.
   PubMed Web of Science ®Google Scholar
• SANDS H, GOREY-FERET LJ, COCUZZA AJ, HOBBS FW,CHIDESTER D, TRAINOR GL: Biodistribution and meta-bolism of internally [3H-1-labeled oligonucleotides. L Comparison of a phosphodiester and a phos-phorothioate. Mot Pharmacol. (1994) 45:932–943.
   Web of Science ®Google Scholar
• CROOKE ST: Commentary: regulatory issues affectingoligonucleotides. Antisense Res. Dev. (1993) 3:301–306.
   PubMedGoogle Scholar
• AGRAWAL S, TEMSAMANI J, TANG JY: Pharmacokinetics,biodistribution, and stability of oligodleoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA (1991) 88:7595–7599.
   PubMed Web of Science ®Google Scholar
• COSSUM PA, TRUONG L, OWENS SR, MARKHAM PM, SHEAJP, CROOKE ST: Pharmacokinetics of a [14C)-labeled phosphorothioate oligonucleotide, ISIS 2105, after in-tradermal administration to rats. J. Pharmacol. Exp. They. (1994) 269:89–94.
   PubMed Web of Science ®Google Scholar
• CROOKE ST, GRILLONE LR, TENDOLKAR A, GARRETT A,FRATION MJ, LEEDS J, BARR W11: A pharraacokbietk evaluation of [14C]-labeled afovirsen sodium in patients with genital warts. din. Pharmacol. 7ber. (1994) 56:641–646.
   Google Scholar
• HIJIYA N, ZHANG J, RATAJCZAK MZ, KANT JA, DE R1EL K,HERLYN M, ZON G, GEWIRTZ AM: Biologic and therapeu-tic significance of MYB expression in human mela-noma. Proc. Natl. Acad. Sci. USA (1994) 91:4499–4503.
   PubMed Web of Science ®Google Scholar
• SKORSKI T, NIEBOROWSKA-SKORSICA M, NICOLAIDES NC,SZCZYLIK C, IVERSEN P, IOZZO RV, ZON G, CALABRETTA B: Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1994) 91:4504–4508.
   PubMed Web of Science ®Google Scholar
• STEIN CA, CHENG YC: Antisense oligonucleotides astherapeutic agents - is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• SKUTELLA T, STOHR T, PROBST JC, RAMALHO-ORTIGAOFJ, HOLSBOER F, JIRIKOWSKI GF: Antisense oligode-oxynucleotides for in vivo targeting of corticotropin-re-leasing hormone mRNA: comparison of phosphoro-thioate and 3'-inverted probe performance. Horm. Metab. Res. (1994) 26:460–464.
   PubMed Web of Science ®Google Scholar
• BEAUCAGE S, CARUTHERS M: Tetrahedron Letters (1981)37:3557.
   Google Scholar
• ZON G, GEISER TG: Phosphorothioate oligonucleotides:chemistry, purification, analysis, scale-up and future directions. Anti-cancer Drug Design (1991) 6:539–568.
   PubMedGoogle Scholar
• MA DD, DOAN TL: Antisense oligonucieotide therapies: are they the "magic bullets"? [editorial]. Ann. Intern .Med. (1994) 120:161–163.
   PubMed Web of Science ®Google Scholar
• HELENE C: Control of oncogene expression by antisense nucleic adds. Bur. J. Cancer (1994)11:1721–1726.
   Google Scholar
• CANTIN EM, WOOLF TM: Antisense oligonucleotides as antiviral agents: prospects and problems. Trends Micro-biol. (1993) 1:270–276.
   PubMedGoogle Scholar
• MIRABELLI CK, BENNETT CF, ANDERSON K, CROOKE ST:In vitro and in vivo pbarrnacologic activities of antis-ense oligonucleotides. Anti-cancer Drug Design (1991) 6:647–661.
   PubMedGoogle Scholar
• AGRAWAL S, GOODCHILD J, CIVEIRA MP, THORNTON AH,SARIN PS, ZAMECNIK P C: Oligodeoxynucleoside phos-phoroamidates and phosphorothioates as inhibitors of human inununodeficiency virus. Proc. Natl. Acad. Sci. USA (1988) 85:7079–7083.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, IKEUCHE T, SUN D, SARIN PS, KONOPKA A,MAIZEL J, ZAMECNIK PC: Inhibition of human immu-nodeficiency virus in early infected and chronically Infected cells by antisense oligonucleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA (1989) 86:7790–7794.
   PubMed Web of Science ®Google Scholar
• MATSUKURA M, ZON G, SHINOZUKA K, ROBERT-GUROFF M, SHIMADA T, STEIN C A, MITSUYA H, WONG-STAAL F, COHEN JS, BRODER S: Regulation of viral expression of human immunodeficiency virus in vitro by an ands-ease phosphorothioate oligodeoxynucleotide against rev(art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. USA (1989) 86:4244–4248.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TANG JY: GEM 91 - an antisense oligonu-c.leotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res. Dev. (1992) 2:261–266.
   Google Scholar
• LISZIEWICZ J, SUN D, METELEV V, ZAMECNIK P, GALLO RC, AGRAWAL S: Long-term treatment of human immu-nodefidency virus-infected cells with antisense oli-gonuckotkle phosphorothioates. Proc. Natl. Acad. Sci. USA (1993) 90:3860–3864.
   PubMed Web of Science ®Google Scholar
• LISZIEWICZ J, SUN D, WEICHOLD FF, THIERRY AR, LUSSO P, TANG J, GALLO RC, AGRAWAL S: Antisense oligode-oxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human inununodefi-ciency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA (1994) 91:7942–7946.
   PubMed Web of Science ®Google Scholar
• GALBRAITH WM, HOBSON WC, GICLAS PC, SCHECHTER PJ, AGRAWAL S: Complement activation and hemody-namic changes following intravenous alimirdstration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4:201–206.
   PubMedGoogle Scholar
• COWSERT LM, FOX MC, ZON G, MIRABELLI CK: In vitro evaluation of phosphorothioate oligonucleotides tar-geted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. (1993) 37:171–177.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, CONDON IT, BENNETT CF: Inhibi-tion of protein kinase C-a expression in human A549 cells by antisense oligonuckotides inhibits induction of intercellular adhesion molecule-1 (IC.AM-1) mRNA by phorbol esters. J. Biol. Chem. (1994) 269:16416–16424.
   Google Scholar
• STEYKOWSKI SM, 'ru Y, CONDON TP, BENNETT CF: Block-ing of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleoticles alone or in com-bination with other immunosuppressive modalitites. Immunol. (1994) 153:5336–5346.
   Web of Science ®Google Scholar
• CROOKE ST: Progress in evaluation of the potential of antisense technology [editorial]. Antisense Res. Dev. (1994) 4:145–146.
   PubMedGoogle Scholar
• BLACK LE, DEGEORGE JJ, CAVAGNARO JA, JORDAN A,AHN CH: Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. An-tisense Res. Dev. (1993) 3:399–404.
   PubMedGoogle Scholar
• KAMBHAMPATI RV, CHIU YY, CHEN CW, BLUMENSTEINJJ: Regulatory concerns for the chemistry, manufactur-ing, and controls of oligonucleotide therapeutics for use in clinic-Al studies. Antisense Res. Dev. (1993) 3:405–410.
   PubMedGoogle Scholar